[{"orgOrder":0,"company":"4P-Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"4Living Biotech and Sanofi Enter into a Collaboration Agreement to Demonstrate Potential Clinical Efficacy of Mozobil\u00ae as a Treatment for Acute and Chronic Complications of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"4P-Pharma Announces Total Capital of \u20ac15 Million Successfully Secured in Second Closing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by 4P-Pharma
The financing is intended to support the company's lead product, 4P-004 (liraglutide), which is currently undergoing evaluation in early-stage clinical trials with patients for treating Knee Osteoarthritis.
The collaboration aims to to demonstrate the potential efficacy of Mozobil (plerixafor) in blocking CXCR4 receptor for the treatment of acute and long-lasting complications of COVID-19 in a Phase 2 global clinical trial.